Merck & Co's Options: A Look at What the Big Money is Thinking - Merck & Co (NYSE:MRK)

Group 1 - Financial giants have shown a bullish sentiment towards Merck & Co, with 47% of traders being bullish and 30% bearish in recent options trading [1] - The analysis revealed a total of 23 unusual trades, with 11 puts valued at $512,555 and 12 calls valued at $590,682 [1] - Whales have targeted a price range for Merck & Co between $65.0 and $100.0 over the last three months [2] Group 2 - The volume and open interest data for Merck & Co's options indicate significant liquidity and interest, particularly within the $65.0 to $100.0 strike price range [3] - Recent options activity shows a mix of bullish and bearish sentiments, with notable trades including a bearish call sweep and bullish put sweep [7] Group 3 - Merck & Co operates in various therapeutic areas, including cardiometabolic disease, cancer, and infections, with Keytruda being a major contributor to sales [8] - The company generates 47% of its sales from the US human health sector, which includes pharmaceuticals and vaccines [8] Group 4 - Analysts have set an average target price of $90.0 for Merck & Co, with one analyst recently downgrading the rating to Hold [10][11] - Current trading volume for Merck & Co stands at 3,155,662, with the stock price at $90.62, reflecting a 1.24% increase [13]